TET2 loss-of-function mutations were identified in myeloid and lymphoid hematological malignancies [13], whereas the TET1 overexpression found in mixed lineage leukemia (MLL)-rearranged leukemia is oncogenic [26]. This evidence concerns the gene KMT2A and cancer.